Genome sequences of Anopheles gambiae sister species help to investigate insecticide resistance
Dr Philip Bejon has been appointed as new Director of the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, one of the Wellcome Trust’s major overseas programmes.
This year’s GEM Travel Awards are supporting 12 researchers from 11 countries to participate in the upcoming Genomic Epidemiology of Malaria conference in Hinxton, UK.
International 10-year project unravels biology of disease-causing fly
Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.
In the war against malaria, one small corner of the globe has repeatedly turned the tide, rendering our best weapons moot and medicine on the brink of defeat. Ed Yong travelled to Thailand and Burma to meet the scientists who are trying to eliminate resistant malaria before it defeats our best remaining drug. This story was originally published in Mosaic and is republished under a CC-BY 4.0 licence.
Dr Olivo Miotto discusses key discoveries in the ongoing attempts to understand the genetic basis of artemsinin resistance, including the identification of artemisinin resistant P. falciparum founder populations in Cambodia and the artemisinin resistance marker in the kelch propeller domain.
Findings published today in Nature identify mutations in the PF3D7_1343700 kelch propeller domain or ‘K-13 propeller’ that are associated with experimentally-induced resistance to the frontline malaria drug, artemisinin, and with naturally-occuring artemisinin resistance in Cambodia.
The Wellcome Trust Sanger Institute is accepting applications for the 2014 Sanger Institute Prize. The winner will receive a three month internship with a research group at the Wellcome Trust Sanger Institute during the Summer of 2014.
The competition is open to undergraduate students from low and middle income countries. Entrants should have a strong and demonstrable interest in genomics, and a good command of English.
Scientists have developed a laboratory blood test which will detect whether Plasmodium falciparum malaria parasites in a given patient will be resistant or susceptible to artemisinin, the key drug used to treat malaria. An indicator of artemisinin resistance is the lengthening of the parasite clearance half-life during treatment, the estimation of which currently requires laborious clinical procedures and statistical analyses.